Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Kindler, Hedy L; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; Hall, Michael J; Park, Joon Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do-Youn; Reinacher-Schick, Anke; Tortora, Giampaolo; Algül, Hana; O'Reilly, Eileen M; Bordia, Sonal; McGuinness, David; Cui, Karen; Locker, Gershon Y; Golan, Talia

doi:10.1200/JCO.21.01604

User: Guest

2022

Back
Back to start of result list
Permanent link for displayed object

Title:: Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Document type:: Article; Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Author(s):: Kindler, Hedy L; Hammel, Pascal; Reni, Michele; Van Cutsem, Eric; Macarulla, Teresa; Hall, Michael J; Park, Joon Oh; Hochhauser, Daniel; Arnold, Dirk; Oh, Do-Youn; Reinacher-Schick, Anke; Tortora, Giampaolo; Algül, Hana; O'Reilly, Eileen M; Bordia, Sonal; McGuinness, David; Cui, Karen; Locker, Gershon Y; Golan, Talia
Abstract:: PURPOSE: The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall survival (OS) and other secondary end points. PATIENTS AND METHODS: Patients with a deleterious or suspected deleterious germline BRCA mutation whose disease had not progressed after ≥ 16 weeks of first-line platinum-based chemotherapy were randomly assigned 3:2 to active maintenance olaparib (300 mg twice daily) or placebo. The primary end point was PFS; secondary end points included OS, time to second disease progression or death, time to first and second subsequent cancer therapies or death, time to discontinuation of study treatment or death, and safety and tolerability. RESULTS: In total, 154 patients were randomly assigned (olaparib, n = 92; placebo, n = 62). No statistically significant OS benefit was observed (median 19.0 v 19.2 months; hazard ratio [HR], 0.83; 95% CI, 0.56 to 1.22; P = .3487). Kaplan-Meier OS curves separated at approximately 24 months, and the estimated 3-year survival after random assignment was 33.9% versus 17.8%, respectively. Median time to first subsequent cancer therapy or death (HR, 0.44; 95% CI, 0.30 to 0.66; P < .0001), time to second subsequent cancer therapy or death (HR, 0.61; 95% CI, 0.42 to 0.89; P = .0111), and time to discontinuation of study treatment or death (HR, 0.43; 95% CI, 0.29 to 0.63; P < .0001) significantly favored olaparib. The HR for second disease progression or death favored olaparib without reaching statistical significance (HR, 0.66; 95% CI, 0.43 to 1.02; P = .0613). Olaparib was well tolerated with no new safety signals. CONCLUSION: Although no statistically significant OS benefit was observed, the HR numerically favored olaparib, which also conferred clinically meaningful benefits including increased time off chemotherapy and long-term survival in a subset of patients.
Journal title abbreviation:: J Clin Oncol
Year:: 2022
Journal volume:: 40
Journal issue:: 34
Pages contribution:: 3929-3939
Fulltext / DOI:: doi:10.1200/JCO.21.01604
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/35834777
Print-ISSN:: 0732-183X
TUM Institution:: Lehrstuhl für Tumormetabolismus (Prof. Algül)
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Innere Medizin II, Gastroenterologie (Prof. Schmid)Lehrstuhl für Tumormetabolismus (Prof. Algül)2022